@article{作者georgep5.2 - 036 = {Ilena乔治和穆罕默德·穆尼尔El Mendili克里斯蒂娜代理和克里斯汀Lebrun Frenay和Orhun Kantarci和Aksel湿婆和达林奥田硕和丹尼尔Pelletier和马蒂尔德Inglese}, title ={小脑体积亏损放射检查孤立综合症(p5.2 - 036)},体积={92}={15}补充数量,elocation-id = {p5.2 - 036} ={2019},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:比较卷RIS颅后窝结构的主题与健康对照组相比。首页背景:放射检查孤立综合征(RIS)通常是一个临床前的多发性硬化症(MS)检测时顺便得到核磁共振成像的原因除了怀疑小脑体积损失女士的女士一直在伴随的运动和认知障碍患者,患者最为明显进步的疾病。小脑体积损失是否可能出现在RIS女士没有临床症状之前调查。设计/方法:21健康个体满足2009标准回顾性确定RIS UCSF女士中心和38岁,sex-matched健康对照组(HC)。受试者扫描在一个3 t通用标记扫描仪使用一个标准化的协议。白质(WM)病变在3 d t1影像分割使用半自动分割技术。Lesion-filled 3 d t1影像划分为灰质(GM), WM和CSF使用统计参数映射(SPM12)软件。小脑通用、WM和脑干成交量计算lesion-filled 3 d t1影像使用一个定制版本的空间无偏Infratentorial SPM12工具箱3.2版本。结果:一般线性模型调整年龄和性别是用来评估的差异规范化infratentorial结构卷RIS和HC之间。所有统计分析完成后使用SPSS (19.0 v,芝加哥,III)。RIS主题显示小脑WM显著减少(p = 0.003)和前小脑通用卷和HC相比(p = 0.005)。显著差异后小脑通用(p = 0.134),小脑通用和脑干总量(p = 0.172) RIS和HC之间并没有观察到。结论:小脑萎缩存在于RIS科目。RIS已经与萎缩在大脑的其他区域,特别是丘脑。 Further longitudinal studies may clarify the significance of these atrophy patterns.Disclosure: Dr. George has nothing to disclose. Dr. El Mendili has nothing to disclose. Dr. Azevedo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi-Genzyme, Biogen Idec, Novartis, and Genentech. Dr. Lebrun Frenay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer Schering, Biogen, Genzyme, Merck Serono, Novartis Pharmaceuticals, and Teva. Dr. Kantarci has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharmaceuticals and Biogen. Dr. Kantarci has received research support from Biogen, the Multiple Sclerosis Society, the Mayo Foundation, and the Hilton Foundation. Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novarti Pharmaceuticals, Teva, Sanofi Genzyme, Bayer, and Roche. Dr. Okuda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received advisory and consulting fees from Celgene, EMD Serono, Genentech, Genzyme, and Novartis. Dr. Okuda has received research support from Biogen. Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Inglese has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Inglese reports grants from Novartis Pharmaceuticals, National Multiple Sclerosis Society, Noto Foundation, NIH and Teva Neuroscience.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/92/15_Supplement/P5.2-036}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }